English

– Nuvaxovid™ COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]) listed for emergency use by the WHO – EUL for Nuvaxovid complements listing for Novavax vaccine manufactured and marketed by Serum Institute of India as Covovax™ – EUL by WHO is a prerequisite for exports to numerous countries participating in the COVAX Facility Novavax, Inc. (Nasdaq: NVAX), a biotechnology company […]

Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) is the first protein-based COVID-19 vaccine authorized for use in Europe Novavax and the European Commission previously announced an advance purchase agreement for up to 200 million doses through 2023 Authorization follows positive recommendation by European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) Novavax, Inc. (Nasdaq: NVAX), […]

European Commission decision on conditional marketing authorization expected imminently Upon authorization, Nuvaxovid™ (also known as NVX-CoV2373) will be the first protein-based COVID-19 vaccine available in Europe Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the European Medicines Agency (EMA) has…